🔎 Trials Near Me

Hjem › Akut myelogen leukemi › North Carolina › Durham

Kliniske studier for Akut myelogen leukemi i Durham, NC

33 studier for Akut myelogen leukemi søker deltakere på steder i og rundt Durham (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

RekruttererFase 2
  • Duke University Medical Center, Durham
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi unna
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT05564390

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
  • Durham VA Medical Center, Durham
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Duke University Medical Center, Durham
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Duke University Medical Center, Durham
Alder 18 til 59 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Duke University Medical Center, Durham
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

RekruttererFase 3
  • Duke University Medical Center, Durham
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi unna
6 Months – 21 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

RekruttererFase 1/2
  • Duke University Medical Center, Durham
30 Days · Alle kjønn · Oppdatert 16. sep. 2026 · NCT04065399

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

RekruttererFase 1
  • University of North Carolina at Chapel Hill, Chapel Hill · 10 mi unna
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT06846606

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

RekruttererFase 1/2
  • UNC School of Medicine, Division of Hematology, Chapel Hill · 10 mi unna
Alder 12 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT04588922

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

RekruttererFase 3
  • US-Chapel Hill-UNCNORTHCAROLINA, Chapel Hill · 10 mi unna
Alder 18 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT06652438

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

RekruttererFase 1/2
  • Duke University Medical Center, Durham
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi unna
Opp til 22 år · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04726241

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

RekruttererFase 1
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi unna
Alder 18 til 75 · Alle kjønn · Oppdatert 25. aug. 2026 · NCT05886049

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

RekruttererFase 3
  • Duke University Medical Center, Durham
  • University of North Carolina, Chapel Hill, Chapel Hill · 10 mi unna
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT07007312

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

RekruttererFase 1
  • University of North Carolina at Chapel Hill, Chapel Hill · 10 mi unna
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT06656494

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

RekruttererFase 1/2
  • Research Site, Durham
  • Research Site, Chapel Hill · 10 mi unna
Alder 16 og eldre · Alle kjønn · Oppdatert 20. jul. 2026 · NCT07155226

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

RekruttererFase 2
  • University of North Carolina at Chapel Hill, Chapel Hill · 10 mi unna
Alder 18 og eldre · Alle kjønn · Oppdatert 10. jul. 2026 · NCT05442216

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

RekruttererObservasjonsstudie
  • Duke University Medical Center, Durham
  • University of North Carolina at Chapel Hill, Chapel Hill · 10 mi unna
Alle aldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT01351545

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

Rekrutterer
  • University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi unna
Alder 60 og eldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT06697600

Registry of Older Patients With Cancer

RekruttererObservasjonsstudie
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi unna
Alder 65 og eldre · Alle kjønn · Oppdatert 29. jun. 2026 · NCT01137825

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

RekruttererFase 2
  • UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · 10 mi unna
Alder 18 og eldre · Alle kjønn · Oppdatert 23. jun. 2026 · NCT05401097

A Study of Revumenib and Mezigdomide in People With Leukemia

RekruttererFase 1/2
  • University of North Carolina (Data Collection Only), Chapel Hill · 10 mi unna
Alder 12 og eldre · Alle kjønn · Oppdatert 22. jun. 2026 · NCT07356154

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

RekruttererFase 1
  • UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · 10 mi unna
Alder 18 og eldre · Alle kjønn · Oppdatert 14. mai 2026 · NCT06222580

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

RekruttererFase 1
  • University of North Carolina, Chapel Hill · 10 mi unna
Alder 13 og eldre · Alle kjønn · Oppdatert 5. mai 2026 · NCT04771572

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

RekruttererFase 2/3
  • Duke University, Durham
Alder 18 og eldre · Alle kjønn · Oppdatert 30. apr. 2026 · NCT04256317

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

RekruttererFase 1/2
  • Duke University, Durham
  • UNC Hospital, Chapel Hill · 10 mi unna
Alder 12 og eldre · Alle kjønn · Oppdatert 24. mar. 2026 · NCT04988555

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

RekruttererFase 1
  • Duke Blood Cancer Center, Durham
Alder 18 og eldre · Alle kjønn · Oppdatert 13. mar. 2026 · NCT05735184

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

RekruttererFase 1
  • Duke Cancer Center, Durham
Alder 18 og eldre · Alle kjønn · Oppdatert 16. jan. 2026 · NCT05143996

Novel Digital Application for Patients With Acute Leukemia

Rekrutterer
  • Duke University, Durham
Alder 18 til 120 · Alle kjønn · Oppdatert 10. nov. 2025 · NCT06472128

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

RekruttererObservasjonsstudie
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi unna
Alder 18 til 120 · Alle kjønn · Oppdatert 27. okt. 2025 · NCT01137643

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

RekruttererFase 1/2
  • Duke University Medical Center, Durham
Alder 18 og eldre · Alle kjønn · Oppdatert 26. aug. 2025 · NCT03850574

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

RekruttererFrivillige helsepersonell ønskes velkommen
  • Duke University, Durham
  • University of North Carolina at Chapel Hill, Chapel Hill · 10 mi unna
Alder 18 til 120 · Alle kjønn · Oppdatert 25. jul. 2025 · NCT05237258

Akut myelogen leukemi-studier i andre byer

Andre studier i Durham

Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.